Zeneca
Executive Summary
Agreement with HealthCare Promotions for contract sales force expanded to include the asthma therapy Accolate (zafirlukast). A 1997 agreement provided for 250 reps to detail Zeneca's cardiovascular line; the new agreement will increase the contract force by 128 reps to promote the leukotriene inhibitor